Intrommune’s mission is to develop safe and effective options for food allergy sufferers so they and their loved ones can live their lives without fear.
Intrommune Therapeutics is a biotechnology company developing patient-friendly therapies for the treatment of food allergies. The company’s oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy. Immunotherapeutic agents are regularly administered to areas of the oral cavity with the highest likelihood of decreasing allergy symptoms, gradually desensitizing the immune system to specific foods.
OMIT is administered via a specially formulated toothpaste that incorporates and stabilizes allergens (food proteins). Intrommune’s technology has been used in over 1,000 patients suffering from respiratory allergies and Intrommune has begun its clinical proof-of-concept study for peanut allergies to scientifically validate the OMIT toothpaste platform approach. Published research demonstrates safety and adherence advantages over other allergy immunotherapies. Intrommune strives to transform lives by meeting the significant health care need for effective food allergy treatments through the oral mucosal immunotherapy (OMIT) platform and lead product INT301.
Q & A With Michael Nelson, JD and Bill Reisacher, MD
NO CATCH. NO RISK. NO-BRAINER!
Boost your crypto portfolio with 100 free Unicoins. Use promo code below to get your certificate.
Any historical returns, expected returns, or probability projections may not reflect actual future performance. These examples are extreme and rare examples of returns that have been realized. It should not be assumed that these types of results are common or that they should be expected. Investing in private companies offers the opportunity to earn a high return on your investment, but also carries significant risks, including lack of liquidity and potential loss of some or all of your investment. Past performance is no guarantee of future results. Please refer to Risks and Disclaimers to learn more about the risks associated with investing in private companies.